Garrido Abad Pablo, Coloma Almudena, Herranz Luis Miguel, Jiménez Milagros, Suárez Carlos, Prieto María Dolores, Formoso Teresa, Fernández Arjona Manuel
Urology Department and Unidad de Enfermería de Urología, Hospital del Henares, Coslada, Madrid, Spain.
Arch Esp Urol. 2012 Oct;65(8):745-51.
To evaluate the treatment of Peyronie's disease (PD) with verapamil and dexamethasone iontophoresis.
Twenty nine patients with PD were treated by means of a Miniphysionize" dispositive 3 sessions a week during 4 consecutive weeks. 5mL of a combination of verapamil(10mg.) and dexamethasone (4mg.) were transdermally administered with a 2.5 mA current during 20 min. The aim is to evaluate treatment efficacy in correcting penile curvature (Kelami test), plaque size (penis ultrasound (US)) improvement of pain and, other parameters like erectile function (EF), intercourse capacity or adverse effects of the treatment, which were evaluated with questionnaires.
All patients completed the treatment protocol (12 sessions) and a total number of 348 sessions of iontophoresis were performed. After treatment, 3 patients (10.7%) continued with pain, but it disappeared in 25 of them (89.3%). A decrease of the size of the plaque was observed in 13 patients (44.8%), even disappearance in 4 patients (13.8%). No patient had curvature decrease after treatment. However, EF (IIEF score) and ability for intercourse improved in 3 (10.3%) and 4 patients (13.8%) respectively.
Verapamil and dexamethasone iontophoresis is a safe and reliable treatment resolving painful erections in the acute phase of PD. However its efficacy in solving penile curvature and erectile dysfunction (ED) is more limited.
评估维拉帕米和地塞米松离子导入疗法治疗佩罗尼氏病（PD）的效果。
29例PD患者采用“Miniphysionize”设备进行治疗，每周3次，连续4周。将5毫升维拉帕米（10毫克）和地塞米松（4毫克）的混合液通过2.5毫安电流进行20分钟的经皮给药。目的是评估治疗在矫正阴茎弯曲（凯拉米试验）、斑块大小（阴茎超声（US））、疼痛改善以及勃起功能（EF）、性交能力或治疗不良反应等其他参数方面的疗效，这些通过问卷调查进行评估。
所有患者均完成治疗方案（12次治疗），共进行了348次离子导入治疗。治疗后，3例患者（10.7%）仍有疼痛，但25例患者（89.3%）疼痛消失。13例患者（44.8%）斑块大小减小，4例患者（13.8%）斑块甚至消失。治疗后无患者阴茎弯曲度减小。然而，EF（国际勃起功能指数评分）和性交能力分别在3例患者（10.3%）和4例患者（13.8%）中得到改善。
维拉帕米和地塞米松离子导入疗法是一种安全可靠的治疗方法，可解决PD急性期的疼痛性勃起。然而，其在解决阴茎弯曲和勃起功能障碍（ED）方面的疗效更为有限。
